# RCT Glargine vs NPH for Treatment of DM in Pregnancy

Study · id `cardio:ct-nct06619301` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT06619301](<https://clinicaltrials.gov/study/NCT06619301>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT06619301

Browse, organ or system: Metabolism  
Browse, condition area: Diabetes and metabolic disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 160 participants.

## Technical summary

Registry record NCT06619301. Randomized; no masking; primary purpose treatment. Start 2024-04-01 (actual); primary completion 2026-04-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 3
- Enrolled: 160 participants (planned count; ClinicalTrials.gov record NCT06619301, source copy `cardio:ctgov-nct06619301-2024-10-01`, retrieved 2026-10-26)
- Started: 2024-04-01 (actual) (ClinicalTrials.gov record NCT06619301, source copy `cardio:ctgov-nct06619301-2024-10-01`, retrieved 2026-10-26)
- Primary completion: 2026-04-01 (anticipated) (ClinicalTrials.gov record NCT06619301, source copy `cardio:ctgov-nct06619301-2024-10-01`, retrieved 2026-10-26)
- Completion: 2027-01-01 (anticipated) (ClinicalTrials.gov record NCT06619301, source copy `cardio:ctgov-nct06619301-2024-10-01`, retrieved 2026-10-26)
- Countries: United States (ClinicalTrials.gov record NCT06619301, source copy `cardio:ctgov-nct06619301-2024-10-01`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct06619301-2024-10-01`, retrieved 2026-10-26)

## The registry's words

- Brief title: RCT Glargine vs NPH for Treatment of DM in Pregnancy
- Condition: Diabetes Mellitus in Pregnancy
- Condition: Type 2 Diabetes Mellitus (T2DM)
- Condition: Gestational Diabetes Mellitus, Class A2
- Intervention (Drug): Insulin glargine
- Intervention (Drug): insulin NPH
- Lead sponsor: Loyola University
- Lead sponsor class: OTHER

## Connected pages

- Registry condition terms include this condition: Type 2 diabetes (`cardio:type-2-diabetes`)
- Registry lists this organization as the lead sponsor: Loyola University (`cardio:org-loyola-university`)

## Provenance

Content hash: 9bf5b69f3ab843c0cec8cfd86f22a047bebcff6f1722841932d26b3a5cfbda1e
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
